View Item 

Show simple item record

The Molecular Adsorbents Recycling System as a Liver Support System Based on Albumin Dialysis: A Summary of Preclinical Investigations, Prospective, Randomized, Controlled Clinical Trial, and Clinical Experience from 19 Centers
dc.contributor.authorStange, Janen_US
dc.contributor.authorHassanein, Tarek i.en_US
dc.contributor.authorMehta, Ravindraen_US
dc.contributor.authorMitzner, Steffen r.en_US
dc.contributor.authorBartlett, Robert H.en_US
dc.date.accessioned2010-06-01T20:46:08Z
dc.date.available2010-06-01T20:46:08Z
dc.date.issued2002-02en_US
dc.identifier.citationStange, Jan; Hassanein, Tarek I . ; Mehta, Ravindra; Mitzner, Steffen R . ; Bartlett, Robert H . (2002). "The Molecular Adsorbents Recycling System as a Liver Support System Based on Albumin Dialysis: A Summary of Preclinical Investigations, Prospective, Randomized, Controlled Clinical Trial, and Clinical Experience from 19 Centers." Artificial Organs 26(2): 103-110. <http://hdl.handle.net/2027.42/73869>en_US
dc.identifier.issn0160-564Xen_US
dc.identifier.issn1525-1594en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73869
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11879237&dopt=citationen_US
dc.description.abstractArtificial liver support aims to prolong survival time of patients with liver failure by detoxification. Albumin as a molecular adsorbent in dialysis solution is capable of attracting even tightly albumin-bound toxins from blood into the dialysate if a specific dialysis membrane is used and if the albumin's binding sites are on-line-purified by a sorbent/dialysis-based recycling system (i.e., molecular adsorbents recycling system, or MARS). The MARS technology has been shown to remove water-soluble and albumin-bound toxins and to provide renal support in case of renal failure. Fourteen centers have reported that MARS treatment improved mental status of patients with liver failure and hepatic encephalopathy. In treating liver failure and cholestasis, MARS was associated with hemodynamic stabilization, improvement of hepatic and kidney function, and disappearance of pruritus. In hepatic failure and hepatorenal syndrome, a prospective, randomized, controlled trial of MARS treatment was able to prolong survival time significantly. MARS has been used in 26 patients with acute liver failure or primary graft dysfunction. Nineteen centers reporting on 103 patients have shown that MARS treatment is safe, easy to handle, feasible, and effective.en_US
dc.format.extent145233 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing, Inc.en_US
dc.rights2002 International Society for Artificial Organsen_US
dc.subject.otherAlbumin Dialysisen_US
dc.subject.otherClinical Trialsen_US
dc.subject.otherLiver Failureen_US
dc.subject.otherLiver Supporten_US
dc.subject.otherMolecular Adsorbents Recycling Systemen_US
dc.subject.otherMulticenter Trialsen_US
dc.titleThe Molecular Adsorbents Recycling System as a Liver Support System Based on Albumin Dialysis: A Summary of Preclinical Investigations, Prospective, Randomized, Controlled Clinical Trial, and Clinical Experience from 19 Centersen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum§ Department of Surgery, University of Michigan Hospitals, Ann Arbor, Michigan, U.S.A.en_US
dc.contributor.affiliationother* Division of Gastroenterology, Hepatology;en_US
dc.contributor.affiliationother† Division of Nephrology, UCSD Medical Center, San Diego, California, U.S.A.;en_US
dc.contributor.affiliationother† Division of Nephrology, Department of Internal Medicine, University of Rostock, Rostock, Germany; anden_US
dc.identifier.pmid11879237en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73869/1/j.1525-1594.2002.06822.x.pdf
dc.identifier.doi10.1046/j.1525-1594.2002.06822.xen_US
dc.identifier.sourceArtificial Organsen_US
dc.identifier.citedreferenceOpolon P. High-permeability membrane hemodialysis and hemofiltration in acute hepatic coma: experimental and clinical results. Artif Organs 1979; 3 ( 4 ): 354 – 60.en_US
dc.identifier.citedreferenceBrunner G. What is needed for an artificial liver? In: Nose Y, Kjellstrand C, Ivanovich P, eds. Progress in artificial organs 1985. Cleveland: ISAO Press, 1986.en_US
dc.identifier.citedreferenceWinchester JF, Ratcliffe JG, Carlyle E, Kennedy AC. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia. Kidney Int 1978; 14 ( 1 ): 74 – 81.en_US
dc.identifier.citedreferenceShiga Y, Fujihara K, Onodera H, Nagata T, Itoyama Y. Complement activation as a cause of transient hypotension during plasmapheresis. Artif Organs 1998; 22 ( 12 ): 1067 – 9.en_US
dc.identifier.citedreferenceUeno S, Tanabe G, Hanazono K, Ogawa H, Yoshidome S, Aikou T, Yoshida A. Postoperative management following massive hepatectomy in a patient with Dubin-Johnson syndrome: report of a case. Surg Today 1998; 28 ( 12 ): 1274 – 8.en_US
dc.identifier.citedreferenceBinimelis J, Bassas L, Marruecos L, Rodriguez J, Domingo ML, Madoz P, Armengol S, Mangues MA, de Leiva A. Massive thyroxine intoxication: evaluation of plasma extraction. Intensive Care Med 1987; 13 ( 1 ): 33 – 8.en_US
dc.identifier.citedreferencePreuschof L, Keller F, Bogner U, Reuter E, Offermann G. Plasma exchange and hemoperfusion in iodine-induced thyrotoxicosis. Blood Purif 1991; 9 ( 3 ): 164 – 8.en_US
dc.identifier.citedreferenceBurman KD, Yeager HC, Briggs WA, Earll JM, Wartofsky L. Resin hemoperfusion: a method of removing circulating thyroid hormones. J Clin Endocrinol Metab 1976; 42 ( 1 ): 70 – 8.en_US
dc.identifier.citedreferenceMorachiello P, Landini S, Fracasso A, Righetto F, Scanferla F, Toffoletto P, Genchi R, Bazzato G. Combined hemodialysis-hemoperfusion in the treatment of secondary hyperparathyroidism of uremic patients. Blood Purif 1991; 9 ( 3 ): 148 – 52.en_US
dc.identifier.citedreferenceDixit V, Chang TMS. In vitro and clinical studies of the removal of cortisol, thyroxine, insulin, and thyroid-stimulating hormone by coated charcoal haemoperfusion. Life Support Syst 1984; 2 ( 4 ): 238 – 44.en_US
dc.identifier.citedreferenceKokot F, Nieszporek T. Influence of hemoperfusion on the concentrations of calcitonin, testosterone and cortisol in blood plasma. Artif Organs 1979; 3 ( 4 ): 332 – 5.en_US
dc.identifier.citedreferenceAsh SR, Blake DE, Carr DJ, Carter C, Howard T, Makowka L. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 1992; 15 ( 3 ): 151 – 61.en_US
dc.identifier.citedreferenceKramer L, Gendo A, Funk G, Madl C, Falkenhagen D, Gangl A. Clinical experience with artificial liver support in chronic liver failure with encephalopathy. ASAIO J 1997; 46 ( 2 ): 211.en_US
dc.identifier.citedreferenceFalkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Serner FJ, Schoenhofen M. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999; 23 ( 1 ): 81 – 6.en_US
dc.identifier.citedreferenceWatanabe FD, Arnaout WS, Ting P, Navarro A, Khalili T, Kamohara Y, Kahaku E, Rozga J, Demetriou AA. Artificial liver. Transplant Proc 1999; 31 ( 1–2 ): 371 – 3.en_US
dc.identifier.citedreferenceSussman NL, Kelly JH. Extracorporeal liver support: cell-based therapy for the failing liver. Am J Kidney Dis 1997; 30 ( 5 suppl 4 ): 66 – 71.en_US
dc.identifier.citedreferenceStange J, Mitzner S, Ramlow W, Schmidt R, Klinkmann H. Dialysis against an on line recycled albumin circle enables removal of protein bound toxins. Artif Organs 1993; 17 ( 9 ): 809 – 13.en_US
dc.identifier.citedreferenceStange J, Mitzner S. Mass transfer of albumin bound toxins through membranes-comparison between hemofiltration and the MARS-system. ASAIO J 1995; 41 ( 1 ): 11.en_US
dc.identifier.citedreferenceReimann A, Betz S, Raff M. Removal of albumin bound toxins by extended dialysis. Int J Artif Organs 1995; 18: 465.en_US
dc.identifier.citedreferenceAwad S, Rich PB, Kolla S, Younger JG, Reickert CA, Downing VP, Bartlett RH. Characteristics of an albumin dialysate hemodiafiltration system for the clearance of unconjugated bilirubin. ASAIO J 1997; 43: M745 – 9.en_US
dc.identifier.citedreferenceStange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs 1996; 19: 677 – 91.en_US
dc.identifier.citedreferenceSteiner C, Stange J, Mitzner S, Schmidt R. Role of albumin for transport and distribution of protein bound substances between compartments. Z Gastroenterol Suppl 2001; 39: 52.en_US
dc.identifier.citedreferenceSchmidt LE, Sorensen VR, Svendsen LB, Larsen FS, Stange J, Hansen BA. Improvement of systemic vascular resistance and arterial pressure in patients with acute on chronic liver failure during treatment with the molecular adsorbent recycling system. Hepatology 2000; 32 ( 4 pt 2 ): 401A.en_US
dc.identifier.citedreferenceStange J, Mitzner S, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, Peszynski P, Freytag J, Hickstein H, Lohr M, Liebe S, Schareck W, Hopt UT, Schmidt R. Molecular adsorbent recycling system (MARS)—A new membrane based blood purification system for bioartificial liver support—clinical results. Artif Organs 1999; 23 ( 4 ): 319 – 30.en_US
dc.identifier.citedreferencePeszynski P, Stange J, Mitzner S, Klammt S, Majcher-Peszyuska J, Wacke R, Drewelow B, Schmidt R. Removal of benzodiazepine-like substances as a cause of improvement of hepatic encephalopathy during albumin dialysis. Z Gastroenterol Suppl 2001; 39: 53.en_US
dc.identifier.citedreferenceKreymann B, Seige M, Schweigart U, Kopp KF, Classen M. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein bound toxins. J Hepatology 1999; 31: 1 – 6.en_US
dc.identifier.citedreferenceStange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993; 39: M621 – 5.en_US
dc.identifier.citedreferenceStange J, Mitzner S, Klammt S, Peszynski P, Freytag J, Hickstein H, Hentschel J, Schulz M. Inhibition of NO synthase by arginine removal by liver support (MARS) seems to be only a cofactor for reversal of hypotension in decompensated liver cirrhosis that seems to be linked more to removal of protein bound toxins. Hepatology 2000; 32 ( 4 pt 2 ): 612A.en_US
dc.identifier.citedreferenceAwad SS, Sawada S, Solded OS, Rich PB, Klein R, Alarcon WH, Wang SC, Bartlett RH. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? ASAIO J 1999; 45: 47 – 9.en_US
dc.identifier.citedreferenceSchmidt LE, Svendsen LB, Sorensen VR, Mitzner S, Hansen BA, Larsen FS. The effect of the molecular adsorbent recycling system (MARS) on cerebral perfusion in patients with acute on chronic liver failure and hepatic encephalopathy. Hepatology 2000; 32 ( 4 pt 2 ): 612A.en_US
dc.identifier.citedreferenceAwad S, Soldes O, Sawata S, Rich P, Hirschl R, Bartlett R. Evaluation of an extracorporeal liver assist device using selective hemodiafiltration in an animal model of hepatic failure. ASAIO J 1988; 44: 90A.en_US
dc.identifier.citedreferenceAwad S, Hemmila M, Soldes O, Sawata S, Rich P, Mahler S, Gargulinski M, Hirschl R, Bartlett R. A novel stable reproducible model of hepatic failure in canines. J Surg Res 2000; 94: 167 – 71.en_US
dc.identifier.citedreferenceMitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Lohr JM, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6 ( 3 ): 277 – 86.en_US
dc.identifier.citedreferenceStange J, Mitzner SR, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, Korten G, Schmidt R, Hentschel J, Schulz M, Lohr M, Liebe S, Schareck W, Hopt UT. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 2000; 6 ( 5 ): 603 – 13.en_US
dc.identifier.citedreferenceSorkine P, Abraham RB, Szold O, Biderman P, Kidron A, Merchav H, Brill S, Oren R. Role of molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Z Gastroenterol Suppl 2001; 39: 40 – 41.en_US
dc.identifier.citedreferenceAwad SS, Swaniker F, Bartlett RH. Results of a phase I trial evaluating an extracorporeal hepatic support device utilizing albumin dialysis. Z Gastroenterol Suppl 2001; 39: 22 – 23.en_US
dc.identifier.citedreferenceNovelli G, Rossi M, Pretagostini R, Poli L, Peritore D, Di Nicuolo A, Iappelli M, Cortesini R. Use of MARS in the treatment of acute liver failure: preliminary monocentric experience. Z Gastroenterol Suppl 2001; 39: 39.en_US
dc.identifier.citedreferenceManz T, Bisse E, Ochs A, Cicco A, Grotz W. MARS for treatment of fulminant Wilson crisis. Z Gastroenterol Suppl 2001; 39: 49.en_US
dc.identifier.citedreferenceSiewert-Delle A, Henriksson BA, Baeckmann L. Albumin dialysis with the MARS for a patient with acute liver failure due to paracetamol intoxication: a case report. Z Gastroenterol Suppl 2001; 39: 48.en_US
dc.identifier.citedreferenceLoock J, Treichel U, Gerken G, Broelsch CE, Phillip Th, Heemann U. Treatment of split liver recipients with poor graft function by albumin dialysis (MARS). Z Gastroenterol Suppl 2001; 39: 18 – 19.en_US
dc.identifier.citedreferenceKasakoff L, Hommann M, Wagner Th, Konig V, Schmidt K, Scheele J. Application of artificial liver support (MARS) after split-liver transplantation in an infant. Z Gastroenterol Suppl 2001; 39: 50.en_US
dc.identifier.citedreferenceJost U, Sehreiter D, Scheibner L, Lamesch P, Hauss J. Continous venovenous hemofiltration with extracorporeal albumin dialysis “MARS” in critically ill patients before and after liver transplantation. Z Gastroenterol Suppl 2001; 39: 43.en_US
dc.identifier.citedreferenceDelafosse B, Garnier E, Dumortier J, Boillot O. Edouard Herriot experience with the MARS in 5 patients experiencing hepatic failure. Z Gastroenterol Suppl 2001; 39: 38.en_US
dc.identifier.citedreferenceHuster D, Schubert C, Achenbach H, Caca K, MÖssner J, Berr F. Successful clinical application of extracorporeal albumin dialysis in a patient with benign recurrent intrahepatic cholestasis (BRIC). Z Gastroenterol Suppl 2001; 39: 13 – 14.en_US
dc.identifier.citedreferenceNotohamiprodjo M, Banayosy A, Kizner L, Schuller V, Korfer R. One year experience with MARS therapy in patients with multiorgan failure in Cardiac Center Bad Oyenhausen. Z Gastroenterol Suppl 2001; 39: 51.en_US
dc.identifier.citedreferenceMiyoshi H, Bronk SF, Roberts PJ, Svingen PA, Faubion WA, Guicciardi ME. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103: 137 – 45.en_US
dc.identifier.citedreferenceStamler JS, Jaraki O, Osborne J, Simon D, Keaney J, Vita J, Singel D, Valeri CR, Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an s-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89: 7674 – 7.en_US
dc.identifier.citedreferenceBomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994; 20: 1343 – 50.en_US
dc.identifier.citedreferenceSeige M, Kreymann B, Jeschke B, Schweigart U, Kopp KF, Classen M. Long term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Transplant Proc 1999; 31: 1371 – 5.en_US
dc.identifier.citedreference50.  Klammt S, Mitzner S, Stange J, Peszynski P, Freytag J, Steiner C, Adam U, Hopt UT, Schmidt R. Blood purification in excretory liver insufficiency by albumin dialysis: impact of the dialysis membrane. Hepatology 32(4 pt 2):167A.en_US
dc.identifier.citedreferenceAviles J, Macia M, Perez F, Moreno A, Navarro JF, Morales S, Medina ML, Aguiar R, Garcia J. Efficacy of MARS in 3 patients with hepatorenal syndrome and hepatic encephalopathy: first experience in Spain. Z Gastroenterol Suppl 2001; 39: 20 – 21.en_US
dc.identifier.citedreferenceOliviero A, Mercurio G, Pilato F, Accurso A, Saturno E, Pennisi MA, Mignani V, Gaspan R, Gasbarrini A, Di Campli C, Caminiti G, Gentiloni N, Di Lazzaro V. Motor cortex excitability in severe liver failure: effects of Molecular Adsorbents Recycling System. Z Gastroenterol Suppl 2001; 39: 47.en_US
dc.identifier.citedreferenceGaspari R, Pennisi MA, Mignani V, Gasparrini A, Mercurio G, Di Campli C, Conti G, Gentiloni Silveni N, Proietti R. Artificial liver support as a bridge to orthotopic liver transplantation in a case of acute non-alcoholic steatohepatitis (NASH). Z Gastroenterol Suppl 2001; 39: 15.en_US
dc.identifier.citedreferenceJalan R, Kapoor D, Steiner C, Williams R. MARS in decompensated alcoholic liver disease with multiorgan failure. Z Gastroenterol Suppl 2001; 39: 12.en_US
dc.identifier.citedreferenceUllench H, Avenhaus W, Menzel J, Lerch M, Domschke W. Employment of MARS (Molecular Adsorbents Recycling System) for replacement of liver detoxification function up to orthothopic liver transplantation. Z Gastroenterol Suppl 2001; 39: 46.en_US
dc.identifier.citedreferenceWilmer A, Nevens F, Maes B, Yap P. Molecular Adsorbents Recycling System (MARS) for acute on chronic alcoholic hepatitis: a case report. Z Gastroenterol Suppl 2001; 39: 45.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1525-1594.2002.06822.x.pdf
Size:
141.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.